These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 20665056)
1. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. Sala G; Brighina L; Saracchi E; Fermi S; Riva C; Carrozza V; Pirovano M; Ferrarese C J Neural Transm (Vienna); 2010 Sep; 117(9):1093-8. PubMed ID: 20665056 [TBL] [Abstract][Full Text] [Related]
2. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625 [TBL] [Abstract][Full Text] [Related]
3. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785 [TBL] [Abstract][Full Text] [Related]
4. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. Lev N; Barhum Y; Pilosof NS; Ickowicz D; Cohen HY; Melamed E; Offen D J Gerontol A Biol Sci Med Sci; 2013 Mar; 68(3):215-25. PubMed ID: 22887838 [TBL] [Abstract][Full Text] [Related]
5. Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells. Ishikawa S; Tanaka Y; Takahashi-Niki K; Niki T; Ariga H; Iguchi-Ariga SM Biochem Biophys Res Commun; 2012 May; 421(4):813-8. PubMed ID: 22554508 [TBL] [Abstract][Full Text] [Related]
6. Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan. Kariya S; Hirano M; Takahashi N; Furiya Y; Ueno S J Neurol Sci; 2005 May; 232(1-2):91-4. PubMed ID: 15850588 [TBL] [Abstract][Full Text] [Related]
7. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle. Lohr KM; Miller GW Expert Rev Neurother; 2014 Oct; 14(10):1115-7. PubMed ID: 25220836 [TBL] [Abstract][Full Text] [Related]
8. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder]. Lorenzo-Sanz G; Sánchez-Herranz A Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590 [TBL] [Abstract][Full Text] [Related]
9. Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Smith GS; Mills KA; Pontone GM; Anderson WS; Perepezko KM; Brasic J; Zhou Y; Brandt J; Butson CR; Holt DP; Mathews WB; Dannals RF; Wong DF; Mari Z Parkinsonism Relat Disord; 2019 Jul; 64():235-241. PubMed ID: 31053531 [TBL] [Abstract][Full Text] [Related]
11. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport. Bernstein AI; Stout KA; Miller GW J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664 [TBL] [Abstract][Full Text] [Related]
12. Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. Hu T; Chen Y; Ou R; Wei Q; Cao B; Zhao B; Wu Y; Song W; Chen X; Shang HF J Neurol Sci; 2017 Jun; 377():65-71. PubMed ID: 28477711 [TBL] [Abstract][Full Text] [Related]
13. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine. Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940 [TBL] [Abstract][Full Text] [Related]
14. Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone. Schwartz K; Herman I; Peer G; Weizman A; Rehavi M J Neural Transm (Vienna); 2007 Feb; 114(2):281-4. PubMed ID: 16855915 [TBL] [Abstract][Full Text] [Related]
15. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315 [TBL] [Abstract][Full Text] [Related]
16. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice. Kariya S; Takahashi N; Hirano M; Ueno S J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597 [TBL] [Abstract][Full Text] [Related]
17. The expression of vesicular glutamate transporter 3 and vesicular monoamine transporter 2 induced by brain-derived neurotrophic factor in dorsal root ganglion neurons in vitro. Liu D; Bi Y; Liu Z; Liu H; Li Z Brain Res Bull; 2014 Jan; 100():93-106. PubMed ID: 24316448 [TBL] [Abstract][Full Text] [Related]
18. hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Xiong N; Li N; Martin E; Yu J; Li J; Liu J; Lee DY; Isacson O; Vance J; Qing H; Wang T; Lin Z Neurotherapeutics; 2016 Jul; 13(3):623-34. PubMed ID: 27137201 [TBL] [Abstract][Full Text] [Related]